Ravagalimab

Ravagalimab (ABBV-323) is a CD40 antagonist (EC50: 3.7 nM) . Ravagalimab can be used for research of Crohn's disease[1].

Product Specifications

CAS Number

[2050816-56-1]

Product Name Alternative

ABBV-323

UNSPSC

12352203

Target

TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ravagalimab.html

Purity

99.31

Solubility

10 mM in DMSO

Smiles

[Ravagalimab]

Molecular Weight

(146.04 kDa)

References & Citations

[1]Argiriadi MA, et al. CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches. BMC Mol Cell Biol. 2019 Aug 5;20 (1) :29. |[2]Yu X, et al. Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity. Cancer Cell. 2020 Jun 8;37 (6) :850-866.e7.